Zydus Lifesciences Limited (ZYDUSLIFE) - Total Assets
Based on the latest financial reports, Zydus Lifesciences Limited (ZYDUSLIFE) holds total assets worth Rs468.97 Billion INR (≈ $5.07 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zydus Lifesciences Limited - Total Assets Trend (2004–2025)
This chart illustrates how Zydus Lifesciences Limited's total assets have evolved over time, based on quarterly financial data. Also see market value of Zydus Lifesciences Limited for the company's overall valuation and market capitalisation.
Zydus Lifesciences Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Zydus Lifesciences Limited's total assets of Rs468.97 Billion consist of 45.8% current assets and 54.2% non-current assets. Review Zydus Lifesciences Limited (ZYDUSLIFE) total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 2.2% |
| Accounts Receivable | Rs45.85 Billion | 12.3% |
| Inventory | Rs39.44 Billion | 10.6% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs32.24 Billion | 8.7% |
| Goodwill | Rs52.42 Billion | 14.1% |
Asset Composition Trend (2004–2025)
This chart illustrates how Zydus Lifesciences Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ZYDUSLIFE stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zydus Lifesciences Limited's current assets represent 45.8% of total assets in 2025, an increase from 37.4% in 2004.
- Cash Position: Cash and equivalents constituted 2.2% of total assets in 2025, down from 3.3% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 16.0% in 2004.
- Asset Diversification: The largest asset category is goodwill at 14.1% of total assets.
Zydus Lifesciences Limited Competitors by Total Assets
Key competitors of Zydus Lifesciences Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
Zydus Lifesciences Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.94 | 2.27 | 1.09 |
| Quick Ratio | 1.44 | 1.58 | 0.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs88.65 Billion | Rs68.06 Billion | Rs7.84 Billion |
Zydus Lifesciences Limited - Advanced Valuation Insights
This section examines the relationship between Zydus Lifesciences Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.69 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 27.1% |
| Total Assets | Rs372.02 Billion |
| Market Capitalization | $11.96 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Zydus Lifesciences Limited's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Zydus Lifesciences Limited's assets grew by 27.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Zydus Lifesciences Limited (2004–2025)
The table below shows the annual total assets of Zydus Lifesciences Limited from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs372.02 Billion ≈ $4.02 Billion |
+27.05% |
| 2024-03-31 | Rs292.81 Billion ≈ $3.17 Billion |
+13.68% |
| 2023-03-31 | Rs257.56 Billion ≈ $2.79 Billion |
-7.34% |
| 2022-03-31 | Rs277.95 Billion ≈ $3.01 Billion |
+16.37% |
| 2021-03-31 | Rs238.85 Billion ≈ $2.58 Billion |
+0.84% |
| 2020-03-31 | Rs236.87 Billion ≈ $2.56 Billion |
+0.87% |
| 2019-03-31 | Rs234.83 Billion ≈ $2.54 Billion |
+29.99% |
| 2018-03-31 | Rs180.65 Billion ≈ $1.95 Billion |
+18.69% |
| 2017-03-31 | Rs152.21 Billion ≈ $1.65 Billion |
+51.96% |
| 2016-03-31 | Rs100.16 Billion ≈ $1.08 Billion |
+10.71% |
| 2015-03-31 | Rs90.47 Billion ≈ $978.41 Million |
+13.28% |
| 2014-03-31 | Rs79.86 Billion ≈ $863.71 Million |
+8.33% |
| 2013-03-31 | Rs73.72 Billion ≈ $797.28 Million |
+15.57% |
| 2012-03-31 | Rs63.79 Billion ≈ $689.89 Million |
+39.67% |
| 2011-03-31 | Rs45.67 Billion ≈ $493.93 Million |
+22.17% |
| 2010-03-31 | Rs37.38 Billion ≈ $404.29 Million |
+10.49% |
| 2009-03-31 | Rs33.84 Billion ≈ $365.91 Million |
+31.66% |
| 2008-03-31 | Rs25.70 Billion ≈ $277.92 Million |
+27.78% |
| 2007-03-31 | Rs20.11 Billion ≈ $217.50 Million |
+27.86% |
| 2006-03-31 | Rs15.73 Billion ≈ $170.11 Million |
+15.64% |
| 2005-03-31 | Rs13.60 Billion ≈ $147.10 Million |
+1.33% |
| 2004-03-31 | Rs13.42 Billion ≈ $145.16 Million |
-- |
About Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, con… Read more